Metoclopramide treatment of tardive dyskinesia
- 23 October 1981
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 246 (17), 1934-1935
- https://doi.org/10.1001/jama.246.17.1934
Abstract
Five patients with tardive dyskinesia (average age, 64 yr) were treated with a central dopamine blocking agent, metoclopramide HCl. The duration of symptoms ranged from 4-30 mo. A pretreatment disability score was graded (0-4) for buccolingual, extremity and truncal movements and for duration of tongue protrusion. A 59% improvement was achieved in total disability scores. Tongue protrusion demonstrated the most noticeable improvement. The average daily dosage ranged from 20-80 mg given in divided doses. Duration of follow-up ranged from 3-8 months. Apparently metoclopramide may be effective in the treatment of tardive dyskinesia.This publication has 1 reference indexed in Scilit:
- Multiple receptors for dopamineNature, 1979